The DOI matches its Crossref record.
Residual cardiovascular risk
Abstract
Residual cardiovascular risk is often associated with lipid abnormalities, such as atherogenic dyslipidaemia (AD). Dyslipidaemias are one of the determinants of the risk of developing atherosclerotic cardiovascular disease. In addition to low-density lipoprotein (LDL) particles, which are the most atherogenic lipoproteins, other apolipoprotein B-containing lipoproteins [e.g. triglyceride (TG)-rich lipoproteins and their remnants] contribute to intimal cholesterol deposition and to the development of atherosclerosis. Lipoprotein size is a key determinant of atherogenesis, with remnants being able to penetrate the arterial intima and bind to and be retained by connective matrix tissue, thus directly contributing to plaque formation and progression. This is particularly …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Persistent lipid profile abnormalities despite treatment with statins contribute significantly to residual risk of cardiovascular disease and therefore put the emphasis on the clinical importance of adopting therapeutic strategies that are not limited to reducing LDL cholesterol, but which also act on HDL cholesterol and triglycerides [7].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [7]
Citations
Cites
Still being checked.
Cited by
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., & Ben, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054268 · Cited by 94
Perivascular fat imaging by computed tomography (CT): a virtual guide
Kotanidis, C. P., & Antoniades, C. A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15634 · Cited by 58
Amor, A. J., Serra‐Mir, M., Martínez‐González, M. Á., Corella, D., Salas‐Salvadó, J., Fitó, M., Estruch, R., Serra‐Majem, L., Arós, F., Babió, N., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004803 · Cited by 45
Ponte-Negretti, C. I., Wyss, F., Piskorz, D. L., Santos, R. D., Villar, R., Lorenzatti, A., López-Jaramillo, P. A., Toth, P. P., Amaro, A. J. J., Rodrigo, A. K., et al. (2021) · Archivos de cardiología de México · doi:10.24875/acm.21000005 · Cited by 31
La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico
Millán, J., Hernández‐Mijares, A., Ascaso, J. F., Blasco, M., Brea, Á., Rodríguez, Á. D., González‐Santos, P., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.05.002 · Cited by 19
Metadata
- Authors
- Ferrari, R., & Catapano, A. L.
- Affiliations
- University of Ferrara (IT)
- University of Milan (IT)
- Venue
- European Heart Journal Supplements
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-04-12
- Volume
- 18
- Issue
- suppl C
- Pages
- C1-C1
- ISSN
- 1520-765X (ISSN-L)
- 1554-2815
- OpenAlex
- W2339724646
- Cited by
- 13
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2021: 4 · 2020: 1 · 2017: 1 · 2016: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal Supplements (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- residual cardiovascular risk, cardiovascular disease prevention, cardiovascular risk assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Residual cardiovascular risk. https://app.cochat.ai/papers/10.1093/eurheartj/suw010
- The paper
- Ferrari, R., & Catapano, A. L. (2016). Residual cardiovascular risk. European Heart Journal Supplements. https://doi.org/10.1093/eurheartj/suw010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.